"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at a drug called OncoVEX GM-CSF with radiotherapy and cisplatin for head and neck cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
OncoVEX GM-CSF was injected directly into the cancer. The treatment used a virus which had been changed to make a natural substance called
The researchers hoped that the virus would kill cancer cells and the GM-CSF would boost the immune system to help fight the cancer.
In this trial they were using OncoVEX GM-CSF alongside radiotherapy and chemotherapy. The aims of the trial were to find out
- The best dose of OncoVEX GM-CSF to give
- How well OncoVEX GM-CSF worked alongside radiotherapy and chemotherapy for advanced head and neck cancer
Summary of results
The trial team worked out the highest dose of OncoVEX GM-CSF that could be given safely in this situation. They also found that by having these injections alongside standard treatment, cancer came back in fewer people than would usually be expected.
The trial recruited 17 people who had a head and neck cancer that had spread to their
The researchers also injected OncoVEX GM-CSF directly into each person’s cancer on up to 4 separate occasions.
- Scans showed that the cancer had got smaller or disappeared in 14 people
- Out of 15 people who had surgery to remove the lymph nodes in the neck (a neck dissection), the researchers found cancer in the lymph nodes of only 1 person
The trial team followed up the people in the trial for an average of just under 2 ½ years. They found that the cancer hadn’t come back in the head and neck area in any of the people taking part, but in 4 people, the cancer had spread somewhere else in the body.
The researchers concluded that OncoVEX GM-CSF injections can be given safely alongside radiotherapy and chemotherapy. Although this study was small, cancer did respond to treatment in 14 people. So the researchers plan to look at this treatment in trials involving larger numbers of people.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr K Harrington